Fig. 4: The role of NRF2 in FGF21-induced protection on cardiomyocytes against HG/Pal.

Primary cardiomyocytes were isolated and treated with either control or NRF2-specific siRNA and then the cells were cotreated with both HG/Pal and FGF21 for 24 h. Western blotting was used to detect NRF2 expression (a). The expressions of 4-HNE (B&C), cleaved-caspase 3 (b, d), CTGF (b, e), and ANP (b, f) were measured by western blot assay. Data were collected from at least three independent experiments and presented as mean ± SD. *P < 0.05 vs. control in the Con-siRNA group; #P < 0.05 vs. HG/Pal in the Con-siRNA group; @P < 0.05 vs. control in NRF2-siRNA group; &P < 0.05 vs. HG/Pal in the NRF2-siRNA group; $P < 0.05 vs. HG/Pal/ FGF21 in the Con-siRNA group